Long‐acting muscarinic antagonist + long‐acting beta agonist versus long‐acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta‐analysis

By  

RESPIROLOGY (ELECTRONIC), Vol. 20, Iss. 8, 2015-11 ,pp. : 1153-1159

John Wiley & Sons Inc

Access to resources Recommend Favorite

The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden

By Willis Michael   Svensson Marianne   Löthgren Mickael   Eriksson Bo   Berntsson Anders   Persson Ulf  

The European Journal of Health Economics, Vol. 11, Iss. 6, 2010-12 ,pp. : 585-594

Springer Publishing Company

Access to resources Recommend Favorite

“Impact of drug‐reimbursement policies on prescribing: A case‐study of a newly marketed long‐acting injectable antipsychotic among relapsed schizophrenia patients”

By  

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 27, Iss. 1, 2018-01 ,pp. : 95-104

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus

By Seino Yutaka   Nakajima Hiromu   Miyahara Hajime   Kurita Takashi   Bush Mark A.   Yang Fred   Stewart Murray W.    

Current Medical Research and Opinion, Vol. 25, Iss. 12, 2009-12 ,pp. : 3049-3057

Informa Healthcare

Access to resources Recommend Favorite

Efficacy of a long‐acting C‐peptide analogue against peripheral neuropathy in streptozotocin‐diabetic mice

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 8, 2015-08 ,pp. : 781-788

John Wiley & Sons Inc

Access to resources Recommend Favorite